Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | CEO Evernorth | May 12, 2021 | May 13, 2021 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date May 12, 2021 · Filed May 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | IndirectBy Trust | 29,783 |
Reported balance
After 2021-05-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-05-12 · Gift · Disposed 11,150 · Balance 29,783 |
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 31,484 |
Reported balance
Holding disclosure · report date 2021-05-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 31,484 |
QUEST DIAGNOSTICS INC
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 477 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 135 · Balance 477 F1: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Express Scripts Holding Co.
Report date December 20, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-12-20 transaction · row 5
3 source rows · reconciled sequenceRow 1 · 2018-04-06 · Gift · Disposed 45,327 · Balance 139,736.667 Row 3 · 2018-07-10 · Gift · Disposed 4,482 · Balance 135,254.667 Row 5 · 2018-12-20 · Disposition to issuer · Disposed 135,254.667 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 152,779 |
Reported balance
After 2018-04-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-04-06 · Gift · Acquired 45,327 · Balance 152,779 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 157,261 |
Reported balance
After 2018-07-10 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-07-10 · Gift · Acquired 4,482 · Balance 157,261 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 157,261 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.17 · Expires 2020-03-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-20 · Disposition to issuer · Disposed 33,069 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2021-03-05 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-20 · Disposition to issuer · Disposed 94,140 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.61 · Expires 2022-02-24 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-12-20 · Disposition to issuer · Disposed 43,081 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.83 · Expires 2025-03-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-12-20 · Disposition to issuer · Disposed 106,240 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.57 · Expires 2026-03-09 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-12-20 · Disposition to issuer · Disposed 140,115 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2026-05-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-12-20 · Disposition to issuer · Disposed 123,064 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.62 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-12-20 · Disposition to issuer · Disposed 271,714 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-12-20 · Disposition to issuer · Disposed 2,388.0983 · Balance 0 F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.
F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock.
F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.
Walgreens Boots Alliance, Inc.
Report date August 28, 2025 · Filed August 28, 2025
Section 16 reporting ended · disclosed 2025-08-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-28 transaction · row 1
1 source rowRow 1 · 2025-08-28 · Disposition to issuer · Disposed 1,332,014 · Balance 0 F1: Includes shares underlying restricted stock units ("RSUs"), inclusive of RSUs issued in lieu of dividends. F2: Pursuant to the Agreement and Plan of Merger, dated as of March 6, 2025 (the "Merger Agreement"), by and among Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), Blazing Star Parent, LLC, a Delaware limited liability company ("Parent"), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and the other affiliates of Parent named therein, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F3: At the effective time of the Merger (the "Effective Time") each share of Common Stock was automatically converted into the right to receive from Parent (i) $11.45 in cash, without interest thereon and subject to all applicable withholding (the "Per Share Cash Consideration"), and (ii) one divested asset proceed right issued by Parent or one of its affiliates subject to and in accordance with the divested asset proceed rights agreement (each, a "Divested Asset Proceed Right" and, collectively with the Per Share Cash Consideration, the "Per Share Consideration"). F4: Pursuant to the Merger Agreement, each RSU owned by the reporting person at the Effective Time was cancelled in exchange for the Per Share Consideration, provided that, payment of such consideration with respect to any RSUs that were unvested as of the Effective Time will remain subject to the Reporting Person's continued service as an employee, consistent with the vesting conditions applicable to such RSU immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares underlying restricted stock units ("RSUs"), inclusive of RSUs issued in lieu of dividends.
F2: Pursuant to the Agreement and Plan of Merger, dated as of March 6, 2025 (the "Merger Agreement"), by and among Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), Blazing Star Parent, LLC, a Delaware limited liability company ("Parent"), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and the other affiliates of Parent named therein, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F3: At the effective time of the Merger (the "Effective Time") each share of Common Stock was automatically converted into the right to receive from Parent (i) $11.45 in cash, without interest thereon and subject to all applicable withholding (the "Per Share Cash Consideration"), and (ii) one divested asset proceed right issued by Parent or one of its affiliates subject to and in accordance with the divested asset proceed rights agreement (each, a "Divested Asset Proceed Right" and, collectively with the Per Share Cash Consideration, the "Per Share Consideration").
F4: Pursuant to the Merger Agreement, each RSU owned by the reporting person at the Effective Time was cancelled in exchange for the Per Share Consideration, provided that, payment of such consideration with respect to any RSUs that were unvested as of the Effective Time will remain subject to the Reporting Person's continued service as an employee, consistent with the vesting conditions applicable to such RSU immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 300 | $213.19 | $63,957.72 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 41,594 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $213.12 to $213.29 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:03 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 6,800 | $204.02 | $1,387,325.80 |
DisclosureSEC source: 0001225208-20-008389 · doc4.xml · nonDerivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 41,894 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F5 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $204.42 to $204.845 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:03 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,500 | $204.59 | $511,479.00 |
DisclosureSEC source: 0001225208-20-008389 · doc4.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 48,694 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $203.42 to $204.395 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:03 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 800 | $202.42 | $161,937.60 |
DisclosureSEC source: 0001225208-20-008389 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 51,194 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $201.89 to $202.795 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:03 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 511 | $201.09 | $102,757.19 |
DisclosureSEC source: 0001225208-20-008389 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 51,994 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $200.83 to $201.81 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 27, 2020 Filed Jun 1, 2020 22:03 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 23,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-008389 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 52,505 Read SEC document |
| May 27, 2020 Filed Jun 1, 2020 22:03 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 23,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-008389 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,004 Read SEC document |
| April 30, 2020 Filed May 4, 2020 23:56 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,300 | $200.53 | $260,684.71 |
DisclosureSEC source: 0001225208-20-007036 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 28,566 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $200.03 to $200.84 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 30, 2020 Filed May 4, 2020 23:56 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 800 | $201.87 | $161,492.72 |
DisclosureSEC source: 0001225208-20-007036 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 29,866 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $201.37 to $202.265 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 30, 2020 Filed May 4, 2020 23:56 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 100 | $202.66 | $20,265.50 |
DisclosureSEC source: 0001225208-20-007036 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 30,666 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 6,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003956 · doc4.xml · nonDerivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 30,766 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 6,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003956 · doc4.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,943 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 9,330 | $182.94 | $1,706,830.20 |
DisclosureSEC source: 0001225208-20-003956 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,479 F4 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 7,974 | $179.41 | $1,430,615.34 |
DisclosureSEC source: 0001225208-20-003956 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,809 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 17,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003956 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,783 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,220 | $185.76 | $226,627.20 |
DisclosureSEC source: 0001225208-20-003956 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,966 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,594 | $0.00 Strike: $192.02 | $0.00 |
DisclosureSEC source: 0001225208-20-003815 · doc4.xml · derivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,594 Underlying: Common Stock, $.01 Par Value · 28,594 shares Expires 2030-02-26 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003815 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,186 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 23:06 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 10,298 | $209.57 | $2,158,141.56 |
DisclosureSEC source: 0001225208-20-001962 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 24,230 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2019. F5 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $209.20 to $210.19 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 23:06 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,508 | $208.82 | $1,150,203.14 |
DisclosureSEC source: 0001225208-20-001962 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 34,528 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2019. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $208.20 to $209.195 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 23:06 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,302 | $210.78 | $1,117,546.55 |
DisclosureSEC source: 0001225208-20-001962 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,036 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2019. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $210.22 to $211.19 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 23:06 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 600 | $211.60 | $126,960.36 |
DisclosureSEC source: 0001225208-20-001962 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 45,338 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2019. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $211.23 to $212.12 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 22:16 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 3,910 | $196.31 | $767,572.10 |
DisclosureSEC source: 0001225208-20-001788 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,374 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| January 23, 2020 Filed Feb 6, 2020 22:16 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 21,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-001788 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 45,938 Read SEC document |
| January 23, 2020 Filed Feb 6, 2020 22:16 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 21,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-001788 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,284 Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 22:53 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,879 | $0.00 Strike: $121.14 | $0.00 |
DisclosureSEC source: 0001225208-19-014751 · doc4.xml · derivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 15,879 shares Expires 2020-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on March 6, 2013. The option vested in three equal annual installments on February 28, 2014, February 28, 2015 and February 28, 2016. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 22:53 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 12,436 | $199.15 | $2,476,567.22 |
DisclosureSEC source: 0001225208-19-014751 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,778 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $199.09 to $199.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 22:53 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 15,879 | $121.14 | $1,923,536.01 |
DisclosureSEC source: 0001225208-19-014751 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:53 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 17,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014751 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 24,444 Read SEC document |
| May 03, 2019 Filed May 7, 2019 21:39 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,658 | $152.83 | $253,392.14 |
DisclosureSEC source: 0001567619-19-010048 · doc1.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,335 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:39 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 10,472 | $174.44 | $1,826,735.68 |
DisclosureSEC source: 0001225208-19-004412 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,993 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,246 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004248 · doc4.xml · derivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,246 Underlying: Common Stock, $.01 Par Value · 28,246 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 8,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004248 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,465 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 00:06 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 31,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,287 Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:06 UTC | Cigna Group CI · Entity 550 | GrantPhantom Stock Units · Derivative | 731.2871 | $194.06 Strike: $0.00 | $141,913.57 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · derivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878.2871 Underlying: Common Stock, $.01 Par Value · 731.2871 shares Expires not disclosed F2 · security: Phantom Stock Units credited under Express Scripts Executive Deferred Compensation Plan. F3 · derivative.exercise_price: Upon distribution, each Phantom Stock Unit converts to one share of Cigna Corporation Common Stock. F4 · derivative.exercise_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. F4 · derivative.expiration_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. Read SEC document |
| January 22, 2019 Filed Feb 6, 2019 00:06 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 4,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 42,338 Read SEC document |
| January 22, 2019 Filed Feb 6, 2019 00:06 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 4,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,948 F1 · balance_after: Total holdings were decreased by one share of common stock due to a rounding error on the Form 4 report that was filed on December 26, 2018. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerPhantom Stock Units · Derivative | 2,388.0983 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 14 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 2,388.0983 shares Expires not disclosed F4 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5 · derivative.exercise_price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6 · kind: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F7 · derivative.exercise_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F7 · derivative.expiration_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 271,714 | $0.00 Strike: $67.62 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 13 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 271,714 shares Expires 2027-03-08 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 123,064 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 12 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 123,064 shares Expires 2026-05-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 140,115 | $0.00 Strike: $69.57 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 11 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 140,115 shares Expires 2026-03-09 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 106,240 | $0.00 Strike: $84.83 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 10 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 106,240 shares Expires 2025-03-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 43,081 | $0.00 Strike: $47.61 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 9 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 43,081 shares Expires 2022-02-24 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 94,140 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 8 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 94,140 shares Expires 2021-03-05 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 33,069 | $0.00 Strike: $58.17 | $0.00 |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · derivative · entry 7 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 33,069 shares Expires 2020-03-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 157,261 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · nonDerivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:04 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 135,254.667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-18-000717 · edgar.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:21 UTC | Cigna Group CI · Entity 550 | GrantPhantom Stock Units · Derivative | 1,147 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-18-008713 · doc1.xml · derivative · entry 12 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147 Underlying: Common Stock, $0.01 Par Value · 1,147 shares Expires not disclosed F11 · security: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F1 · derivative.exercise_price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · derivative.exercise_price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F11 · derivative.exercise_price: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F11 · price: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F11 · derivative.exercise_date: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. F11 · derivative.expiration_date: In accordance with the terms of the Merger Agreement, each phantom stock unit outstanding immediately prior to the Effective Time was automatically converted into a phantom stock unit, with the same terms and conditions, relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:21 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 130,477 | Not disclosed Strike: $140.82 | Not disclosed |
DisclosureSEC source: 0001567619-18-008713 · doc1.xml · derivative · entry 11 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,477 Underlying: Common Stock, $0.01 Par Value · 130,477 shares Expires 2027-03-08 F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F10 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase shares of New Cigna Common Stock, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:21 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 59,095 | Not disclosed Strike: $151.48 | Not disclosed |
DisclosureSEC source: 0001567619-18-008713 · doc1.xml · derivative · entry 10 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,095 Underlying: Common Stock, $0.01 Par Value · 59,095 shares Expires 2026-05-04 F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F9 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase shares of New Cigna Common Stock, with the remaining one-third of the option vesting on May 4, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.